Eisai Co., Ltd. (Headquarters: Tokyo, CEO: Haruo Naito, "Eisai") and Biogen Inc. (Nasdaq: BIIB, Headquarters: Cambridge, Massachusetts, CEO: Christopher A. Viehbacher, "Biogen") announced today that the U.S. Food and Drug Administration (FDA) has approved the Biologics License Application (BLA) for once weekly lecanemab-irmb subcutaneous injection (U.S. brand name: LEQEMBI(R) IQLIKTM, pronounced "I Click") for maintenance dosing.
More info..

Eisai Co., Ltd. (Headquarters: Tokyo, CEO: Haruo Naito, "Eisai") announced today that it has received orphan drug designation for anticancer agent the EZH2*1 inhibitor tazemetostat hydrobromide (genericname, product name "Tazverik(R) Tablets 200 mg", "tazemetostat") for unresectable INI1*2-negative epithelioid sarcoma that has progressed after chemotherapy, from the Ministry of Health, Labour and Welfare (MHLW).
More info..

Eisai Co., Ltd. (Headquarters: Tokyo, CEO: Haruo Naito, "Eisai") and Biogen Inc. (Nasdaq: BIIB, Corporate headquarters: Cambridge, Massachusetts, CEO: Christopher A. Viehbacher, "Biogen") announced today that the anti-amyloid beta (AB) monoclonal antibody "LEQEMBI(R)" has been launched in Austria on August 25, 2025 and will be launched in Germany on September 1, 2025.
More info..

Eisai Co., Ltd. (Headquarters: Tokyo, CEO: Haruo Naito, "Eisai") announced today that the in-house discovered and developed orexin receptor antagonist DAYVIGO(R) (brand name in China: "DAYVIGO(R)" generic name: lemborexant) has launched in China for the treatment of adults with insomnia, characterized by difficulties with sleep onset and/or sleep maintenance.
More info..

Eisai Co., Ltd. (Headquarters: Tokyo, CEO: Haruo Naito, "Eisai") announced today that the global revenue (pre-audit basis) of the anti-amyloid-beta protofibril antibody "LEQEMBI(R)" (generic name: lecanemab) was JPY 23.1 billion for the first quarter of fiscal year 2025 (April 1, 2025 - June 30, 2025).
More info..

Eisai Co., Ltd. (Headquarters: Tokyo, CEO: Haruo Naito, "Eisai") and Biogen Inc. (Nasdaq: BIIB, Headquarters: Cambridge, Massachusetts, CEO: Christopher A. Viehbacher, "Biogen") announced today that the latest findings demonstrating the benefits of continuous treatment with lecanemab-irmb (U.S. brand name: LEQEMBI(R)), an anti-amyloid beta (AB) protofibril* antibody for the treatment of early Alzheimer's disease (AD), were presented at the Alzheimer's Association International Conference (AAIC) 2025, held in Toronto, Canada, and virtually
More info..

Eisai Co., Ltd. (Headquarters: Tokyo, CEO: Haruo Naito, "Eisai")and Biogen Inc. (Nasdaq: BIIB, Headquarters: Cambridge, Massachusetts, CEO: Christopher A. Viehbacher,"Biogen") announced today that results on investigational maintenance therapy with subcutaneous autoinjector (SCAI) of lecanemab-irmb (U.S. brand name: LEQEMBI(R)), an anti-amyloid beta (AB) protofibril* antibody for the treatment of early Alzheimer's disease (AD), were presented at the Alzheimer's Association International Conference(AAIC) 2025, held in Toronto, and virtually.
More info..

Eisai Co., Ltd. (Headquarters: Tokyo, CEO: Haruo Naito, "Eisai") and Biogen Inc. (Nasdaq: BIIB, Corporate headquarters: Cambridge, Massachusetts, CEO: Christopher A. Viehbacher, "Biogen") announced today that the two-year real-world study in the U.S of lecanemab (generic name, product name: LEQEBMI(R)), an anti-AB protofibril* antibody, was presented at the Alzheimer's Association International Conference (AAIC) 2025, held in Toronto, Canada and virtually
More info..

Eisai Co., Ltd. (Headquarters: Tokyo, CEO: Haruo Naito, "Eisai") announced today that its in-house discovered tyrosine kinase inhibitor, "LENVIMA(R)" (generic name: lenvatinib mesylate), in combination with the anti-PD-1 antibody, pembrolizumab, and transarterial chemoembolization (TACE) has been approved by the National Medical Products Administration (NMPA) of China for unresectable, non-metastatic hepatocellular carcinoma.
More info..

Eisai Co., Ltd. (Headquarters: Tokyo, CEO: Haruo Naito, "Eisai") announced today that it has been included in the FTSE4Good Index Series for the 24th consecutive year since its initial inclusion in 2002.
More info..

Eisai Co., Ltd. (Headquarters: Tokyo, CEO: Haruo Naito, "Eisai") and KYORIN Pharmaceutical Co., Ltd. (Headquarters: Chiyoda-ku, Tokyo, President and CEO: Yutaka Ogihara, "KYORIN") announced today that Eisai (Thailand) Marketing Co., Ltd. ("Eisai Thailand"), a subsidiary of Eisai, has launched overactive bladder treatment Beova(R) Tablets (generic name vibegron) in Thailand
More info..

Eisai Co., Ltd. (Headquarters: Tokyo, CEO: Haruo Naito, "Eisai") announced today that the company will present the latest findings from its robust Alzheimer's disease (AD) pipeline and research, including our dual-acting, anti-amyloid beta (AB;) protofibril antibody for the treatment of AD, lecanemab (generic name, U.S. brand name: LEQEMBI(R)), and anti-MTBR (microtubule binding region) tau antibody, etalanetug (E2814), at the Alzheimer's Association International Conference (AAIC), being held in Toronto and virtually from July 27-31.
More info..

Eisai Co., Ltd. (Headquarters: Tokyo, CEO: Haruo Naito, "Eisai") announced today that the drug discovery research for Lecanemab (product name: "LEQEMBI"), a humanized anti-human soluble amyloid B (AB) protofibril monoclonal antibody indicated for early Alzheimer's disease (early AD*), which was co-developed by Eisai and BioArctic AB (Headquarters: Sweden; herein after, BioArctic), has received "The 9th Bioindustry Award" from the Japan Bioindustry Association (JBA).
More info..

Eisai Co., Ltd. (Headquarters: Tokyo, CEO: Haruo Naito, "Eisai") announced today that it has launched "URECE" (brand name in China: "Youlesi", generic name: dotinurad) in China as a treatment for Gout.
More info..

Eisai Co., Ltd. (Headquarters: Tokyo, CEO: Haruo Naito, "Eisai") announced that it has been selected for the highest rating of "Supplier Engagement Leader" in the Supplier Engagement Rating by the global environmental non-profit organization CDP.
More info..

Eisai Co., Ltd. announced today the launch of "Pariet S" (pharmaceutical requiring guidance), which is highly effective in alleviating severe heartburn andstomach pain caused by gastric acid reflux, at pharmacies and drugstores throughout Japan.(1)
More info..

Eisai Co., Ltd. announced today that the in-house-discovered and developed orexin receptor antagonist DAYVIGO (generic name: lemborexant) has been approved in China for the treatment of adults with insomnia, characterized by difficulties with sleep onset and/or sleep maintenance.
More info..

Eisai Co., Ltd. announced today the presentation of clinical research across its oncology portfolio and pipeline during the 2025 American Society of Clinical Oncology (ASCO) Annual Meeting (#ASCO25), which is taking place in Chicago, Illinois, and virtually,from May 30 to June 3.
More info..

Eisai Co., Ltd. announced today that it has received notification from Japan's Ministry of Health, Labour, and Welfare (MHLW) that the "all-case surveillance" post-marketing observational study condition required at the time of approval of anticancer agent "Remitoro for Intravenous Drip Infusion 300microgram" (Denileukin Diftitox (Genetical Recombination)) for the indications of T-cell Lymphoma has been cleared.
More info..

Eisai Co., Ltd. announced today that its Representative Corporate Officer and CEO Haruo Naito has been selected to receive the Order of the Rising Sun, Gold and Silver Star at the 2025 Spring Conferment of Decorations.
More info..

Eisai Co., Ltd. and Biogen Inc. announced today that the European Commission (EC) has granted the amyloid-beta (Aβ) monoclonal antibody Leqembi (lecanemab) Marketing Authorization (MA) in the European Union (EU).
More info..

Eisai Co., Ltd. announced today that it has entered into an agreement to divest the rights for proton pump inhibitor Pariet (generic name: rabeprazole sodium) in China to Beijing Peak Biology Pharmaceuticals Co., Ltd., a CBC Group-controlled company.
More info..

Eisai Co., Ltd. announced today that humanized anti- soluble aggregated amyloid-beta (Aβ) monoclonal antibody "LEQEMBI" (lecanemab) for the treatment of early Alzheimer's disease (early AD ) has received the Prime Minister's Award at the 12th Technology Management and Innovation Awards hosted by the Japan Techno-Economics Society (JATES).
More info..

Eisai Co., Ltd. announced today that it has been selected by the Ministry of Economy, Trade and Industry (METI) and the Tokyo Stock Exchange (TSE) as a Nadeshiko Brand 2025 as a listed company excelling in the promotion of women in the workplace.
More info..

Eisai Co., Ltd. announced today that it has been recognized as the 2025 KENKO Investment for Health by Japan's Ministry of Economy, Trade, and Industry (METI) and the Tokyo Stock Exchange, for the first time as a company strategically carrying out efforts with regard to its employees' health from a management perspective.
More info..

Sato Pharmaceutical Co., Ltd. and Eisai Co., Ltd. announced today that they will conclude their co-promotion based on the co-promotion agreement in Japan regarding the orally-administered antifungal agent NAILIN Capsules 100 mg (generic name: fosravuconazole) which is manufactured and marketed by Sato Pharmaceutical, as of March 31, 2025.
More info..

Eisai Co., Ltd. and Biogen Inc. announced today that the Therapeutic Goods Administration (TGA) of Australia has confirmed the initial decision to decline the approval of humanized anti-soluble aggregated amyloid-beta (Abeta) monoclonal antibody lecanemab (generic name) as a treatment for early Alzheimer's disease (AD) (mild cognitive impairment due to AD and mild AD dementia).
More info..

Eisai Co., Ltd. announced today the launch of the new nutritional drink "Chocola BB Nightwell" (designated quasi-drug product), a nutritional drink to help recovery from the accumulated fatigue of the day during sleep, on Monday, March 3.
More info..

Eisai Co., Ltd. and Biogen Inc. announced today that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency has reaffirmed its positive opinion by consensus for the anti-Abeta; monoclonal antibody lecanemab, adopted in November 2024.
More info..